Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation and Depletion: 2009-2022

Historic Depreciation and Depletion for Tg Therapeutics (TGTX) over the last 13 years, with Dec 2022 value amounting to $303,000.

  • Tg Therapeutics' Depreciation and Depletion fell 3.95% to $73,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $246,000, marking a year-over-year decrease of 20.65%. This contributed to the annual value of $303,000 for FY2022, which is 7.45% up from last year.
  • Latest data reveals that Tg Therapeutics reported Depreciation and Depletion of $303,000 as of FY2022, which was up 7.45% from $282,000 recorded in FY2021.
  • In the past 5 years, Tg Therapeutics' Depreciation and Depletion registered a high of $303,000 during FY2022, and its lowest value of $88,000 during FY2018.
  • For the 3-year period, Tg Therapeutics' Depreciation and Depletion averaged around $247,667, with its median value being $282,000 (2021).
  • Data for Tg Therapeutics' Depreciation and Depletion shows a peak YoY skyrocketed of 78.48% (in 2021) over the last 5 years.
  • Tg Therapeutics' Depreciation and Depletion (Yearly) stood at $88,000 in 2018, then grew by 13.64% to $100,000 in 2019, then skyrocketed by 58.00% to $158,000 in 2020, then skyrocketed by 78.48% to $282,000 in 2021, then increased by 7.45% to $303,000 in 2022.